{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:32:30Z","timestamp":1793413950121,"version":"4.5.0"},"reference-count":68,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>The management of age-related macular degeneration (AMD) presents a significant challenge attributable to high disease heterogeneity. Patient realization of symptoms is poor and it is urgent to treat before permanent anatomic damage results in vision loss. This is true for the initial conversion from non-exudative intermediate AMD (iAMD) to exudative AMD (nAMD), and for the recurrence of nAMD undergoing treatment. Starting from the essential requirements that any practical solution needs to fulfill, we will reflect on how persistent navigation towards innovative solutions during a 25-year journey yielded significant advances towards improvements in personalized care. An early insight was that the acute nature of AMD progression requires frequent monitoring and therefore diagnostic testing should be performed at the patient\u2019s home. Four key requirements were identified: (1) A tele-connected home device with acceptable diagnostic performance and a supportive patient user interface, both hardware and software. (2) Automated analytics capabilities that can process large volumes of data. (3) Efficient remote patient engagement and support through a digital healthcare provider. (4) A low-cost medical system that enables digital healthcare delivery through appropriate compensation for both the monitoring provider and the prescribing physician services. We reviewed the published literature accompanying first the development of Preferential Hyperacuity Perimetry (PHP) for monitoring iAMD, followed by Spectral Domain Optical Coherence Tomography (SD-OCT) for monitoring nAMD. Emphasis was given to the review of the validation of the core technologies, the regulatory process, and real-world studies, and how they led to the release of commercial services that are covered by Medicare in the USA. We concluded that while during the first quarter of the 21st century, the two main pillars of management of AMD were anti-VEGF intravitreal injections and in-office OCT, the addition of home-monitoring-based digital health services can become the third pillar.<\/jats:p>","DOI":"10.3390\/medicina61122193","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T12:57:41Z","timestamp":1765457861000},"page":"2193","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Home Monitoring for the Management of Age-Related Macular Degeneration: A Review of the Development and Implementation of Digital Health Solutions over a 25-Year Scientific Journey"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-8486","authenticated-orcid":false,"given":"Miguel A.","family":"Busquets","sequence":"first","affiliation":[{"name":"Retina Associates of Kentucky, Lexington, KY 40509, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-2743","authenticated-orcid":false,"given":"Richard A.","family":"Garfinkel","sequence":"additional","affiliation":[{"name":"Retina Group of Washington, Chevy Chase, MD 20815, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2627-5203","authenticated-orcid":false,"given":"Deepak","family":"Sambhara","sequence":"additional","affiliation":[{"name":"Eye Clinic of Wisconsin, Wausau, WI 54403, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Mohan","sequence":"additional","affiliation":[{"name":"Notal Vision Inc., Manassas, VA 20109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3271-8250","authenticated-orcid":false,"given":"Kester","family":"Nahen","sequence":"additional","affiliation":[{"name":"Notal Vision Inc., Manassas, VA 20109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4496-8462","authenticated-orcid":false,"given":"Gidi","family":"Benyamini","sequence":"additional","affiliation":[{"name":"Notal Vision Inc., Manassas, VA 20109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-1165","authenticated-orcid":false,"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[{"name":"Tel Aviv Medical Center, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ophtha.2004.10.035","article-title":"Heterogeneity of the genetic risk in age-related macular disease","volume":"112","author":"Assink","year":"2005","journal-title":"Ophthalmology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","article-title":"Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results","volume":"144","author":"Kaiser","year":"2007","journal-title":"Am. J. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/bjophthalmol-2014-306229","article-title":"UK AMD EMR USERS GROUP REPORT V: Benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6\/12","volume":"99","author":"Lee","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3928\/23258160-20201104-05","article-title":"Baseline Visual Acuity at Wet AMD Diagnosis Predicts Long-Term Vision Outcomes: An Analysis of the IRIS Registry","volume":"51","author":"Ho","year":"2020","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.oret.2020.03.017","article-title":"Detrimental Effect of Delayed Re-treatment of Active Disease on Outcomes in Neovascular Age-Related Macular Degeneration","volume":"4","author":"Teo","year":"2020","journal-title":"Ophthalmol. Retin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/IAE.0b013e318050d2ec","article-title":"The Significance of Early Detection of Age-Related Macular Degeneration","volume":"27","author":"Loewenstein","year":"2007","journal-title":"Retina"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1001\/jamaophthalmol.2016.5314","article-title":"The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good","volume":"135","author":"Ho","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"ref_9","first-page":"570","article-title":"Visual acuity and hyperacuity","volume":"14","author":"Westheimer","year":"1975","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1001\/archopht.1984.01040030942019","article-title":"Hyperacuity Perimetry","volume":"102","author":"Enoch","year":"1984","journal-title":"Arch. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cct.2014.02.003","article-title":"Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design\u2014HOME Study report number 1","volume":"37","author":"Chew","year":"2014","journal-title":"Contemp. Clin. Trials"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0161-6420(03)00074-5","article-title":"Replacing the Amsler grid","volume":"110","author":"Loewenstein","year":"2003","journal-title":"Ophthalmology"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Preferential Hyperacuity Perimetry Research Group (2005). Preferential Hyperacuity Perimeter (PreView PHP) for Detecting Choroidal Neovascularization Study. Ophthalmology, 112, 1758\u20131765.","DOI":"10.1016\/j.ophtha.2005.06.008"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00006982-200504000-00008","article-title":"Results of a Multicenter Clinical Trial to Evaluate the Preferential Hyperacuity Perimeter for Detection of Age-Related Macular Degeneration","volume":"25","author":"Goldstein","year":"2005","journal-title":"Retina"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ophtha.2011.10.019","article-title":"Detection of New-Onset Choroidal Neovascularization Using Optical Coherence Tomography","volume":"119","author":"Do","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1097\/IAE.0b013e31820d3ed1","article-title":"Functional and Morphologic Benefits in Early Detection of Neovascular Age-Related Macular Degeneration Using the Preferential Hyperacuity Perimeter","volume":"31","author":"Lai","year":"2011","journal-title":"Retina"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1167\/iovs.11-7517","article-title":"Preferential Hyperacuity Perimeter as a Functional Tool for Monitoring Exudative Age-Related Macular Degeneration in Patients Treated by Intravitreal Ranibizumab","volume":"52","author":"Querques","year":"2011","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3928\/15428877-20100830-05","article-title":"Long-Term Monitoring of Age-Related Macular Degeneration with Preferential Hyperacuity Perimetry","volume":"41","author":"Stur","year":"2010","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1097\/IAE.0b013e3181a3b8d4","article-title":"Preferential Hyperacuity Perimetry to Detect Hydroxychloroquine Retinal Toxicity","volume":"29","author":"Anderson","year":"2009","journal-title":"Retina"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/IAE.0b013e3181f441c1","article-title":"Preferential Hyperacuity Perimeter in Best Vitelliform Macular Dystrophy","volume":"31","author":"Querques","year":"2011","journal-title":"Retina"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajo.2012.07.007","article-title":"Preferential hyperacuity perimeter and prognostic factors for metamorphopsia after idiopathic epiretinal membrane surgery","volume":"155","author":"Bae","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/bjo.2010.190942","article-title":"Preferential hyperacuity perimeter in assessing responsiveness to ranibizumab therapy for exudative age-related macular degeneration","volume":"95","author":"Querques","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/IAE.0b013e3181a91dbf","article-title":"Distortion Maps from Preferential Hyperacuity Perimetry are Helpful in Monitoring Functional Response to Lucentis Therapy","volume":"29","author":"Das","year":"2009","journal-title":"Retina"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1097\/IAE.0b013e31822528ea","article-title":"Macular Diseases: Moving the Battlefield to the Patient\u2019s Home","volume":"31","author":"Loewenstein","year":"2011","journal-title":"Retina"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jamaophthalmol.2024.0918","article-title":"Home-Monitoring Vision Tests to Detect Active Neovascular Age-Related Macular Degeneration","volume":"142","author":"Hogg","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1590\/S0004-27492007000500009","article-title":"Comparison of the original Amsler grid with the preferential hyperacuity perimeter for detecting choroidal neovascularization in age-related macular degeneration","volume":"70","author":"Isaac","year":"2007","journal-title":"Arq. Bras. Oftalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1055\/s-2006-926880","article-title":"Comparison of Preferential Hyperacuity Perimeter (PHP) test and Amsler grid test in the diagnosis of different stages of age-related macular degeneration","volume":"223","author":"Kampmeier","year":"2006","journal-title":"Klin. Monbl. Augenheilkd."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/bjo.2006.095315","article-title":"The Amsler chart: Absence of evidence is not evidence of absence","volume":"91","author":"Crossland","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"ref_29","first-page":"397","article-title":"Macular function surveillance revisited","volume":"79","author":"Trevino","year":"2008","journal-title":"Optom.-J. Am. Optom. Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.ophtha.2021.07.025","article-title":"Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration","volume":"128","author":"Sivaprasad","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1097\/IAE.0b013e3181d1a75e","article-title":"Toward Earlier Detection of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration","volume":"30","author":"Loewenstein","year":"2010","journal-title":"Retina"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Chew, E., Clemons, T., and SanGiovanni, J.P. (2013). Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration. JAMA, 309.","DOI":"10.1001\/jama.2013.4997"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ophtha.2013.10.027","article-title":"Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the eye (HOME) study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/IAE.0000000000000940","article-title":"Effectiveness of Different Monitoring Modalities in the Detection of Neovascular Age-Related Macular Degeneration","volume":"36","author":"Chew","year":"2016","journal-title":"Retina"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.oret.2019.01.004","article-title":"Imaging Characteristics of Choroidal Neovascular Lesions in the AREDS2-HOME Study: Report Number 4","volume":"3","author":"Domalpally","year":"2019","journal-title":"Ophthalmol. Retin."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/ICB.0000000000000085","article-title":"Early Detection of Choroidal Neovascularization Facilitated with a Home Monitoring Program in Age-Related Macular Degeneration","volume":"9","author":"Chaikitmongkol","year":"2015","journal-title":"Retin. Cases Brief Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaophthalmol.2014.1405","article-title":"The ForeSeeHome Device and the HOME Study","volume":"132","author":"Han","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ho, A.C., Heier, J.S., Holekamp, N.M., Garfinkel, R.A., Ladd, B., Awh, C.C., Singh, R.P., Sanborn, G.E., Jacobs, J.H., and Elman, M.J. (2021). Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071355"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.oret.2022.04.016","article-title":"Analysis of the Long-term Visual Outcomes of ForeseeHome Remote Telemonitoring","volume":"6","author":"Mathai","year":"2022","journal-title":"Ophthalmol. Retin."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jamaophthalmol.2017.0255","article-title":"Economic Evaluation of a Home-Based Age-Related Macular Degeneration Monitoring System","volume":"135","author":"Wittenborn","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.oret.2022.10.009","article-title":"The Predictive Value of False-Positive ForeseeHome Alerts in the ALOFT Study","volume":"7","author":"Ho","year":"2023","journal-title":"Ophthalmol. Retin."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2024.12.018","article-title":"Age-Related Macular Degeneration Preferred Practice Pattern\u00ae","volume":"132","author":"Vemulakonda","year":"2025","journal-title":"Ophthalmology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"OCTi","DOI":"10.1167\/iovs.16-20269","article-title":"Foreword: 25 Years of Optical Coherence Tomography","volume":"57","author":"Fujimoto","year":"2016","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1038\/s41433-025-03829-8","article-title":"Systematic review of clinical practice guidelines for the management of neovascular age-related macular degeneration","volume":"39","author":"Lim","year":"2025","journal-title":"Eye"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","article-title":"Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration","volume":"1","author":"Wykoff","year":"2017","journal-title":"Ophthalmol. Retin."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2016.04.005","article-title":"Automated Identification of Lesion Activity in Neovascular Age-Related Macular Degeneration","volume":"123","author":"Chakravarthy","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_48","unstructured":"Goldstein, M., Havilio, M., Loewenstein, A., and Rafaeli, O. (2019, January 12\u201315). A novel AI-based algorithm for quantifying volumes of retinal pathologies in OCT scans. Proceedings of the American Academy of Ophthalmology Meeting, San Francisco, CA, USA."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","article-title":"Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD","volume":"35","author":"Chakravarthy","year":"2021","journal-title":"Eye"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000547161","article-title":"The British-Israeli Project for Algorithm-Based Management of Age-Related Macular Degeneration: Deep Learning Integration for Real-World Data Management and Analysis","volume":"248","author":"Zur","year":"2025","journal-title":"Ophthalmologica"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ophtha.2020.06.038","article-title":"Retinal Specialist versus Artificial Intelligence Detection of Retinal Fluid from OCT","volume":"128","author":"Keenan","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41433-024-03532-0","article-title":"Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study","volume":"39","author":"Aziz","year":"2025","journal-title":"Eye"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ajo.2020.12.012","article-title":"Automated Quantitative Assessment of Retinal Fluid Volumes as Important Biomarkers in Neovascular Age-Related Macular Degeneration","volume":"224","author":"Keenan","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kim, J.E., Tomkins-Netzer, O., Elman, M.J., Lally, D.R., Goldstein, M., Goldenberg, D., Shulman, S., Benyamini, G., and Loewenstein, A. (2022). Evaluation of a self-imaging SD-OCT system designed for remote home monitoring. BMC Ophthalmol., 22.","DOI":"10.1186\/s12886-022-02458-z"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100034","DOI":"10.1016\/j.xops.2021.100034","article-title":"Prospective, Longitudinal Pilot Study: Daily Self-Imaging with Patient-Operated Home OCT in Neovascular Age-Related Macular Degeneration","volume":"1","author":"Keenan","year":"2021","journal-title":"Ophthalmol. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.oret.2022.02.011","article-title":"Prospective, Longitudinal Study: Daily Self-Imaging with Home OCT for Neovascular Age-Related Macular Degeneration","volume":"6","author":"Liu","year":"2022","journal-title":"Ophthalmol. Retin."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.14.9.2","article-title":"Optimizing Early Ophthalmology Clinical Trials: Home OCT and Modeling Can Reduce Sample Size by 20% to 40%","volume":"14","author":"Hermes","year":"2025","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.oret.2023.10.012","article-title":"Home OCT Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study","volume":"8","author":"Blinder","year":"2024","journal-title":"Ophthalmol. Retin."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/24741264241302858","article-title":"Clinical Use of Home OCT Data to Manage Neovascular Age-Related Macular Degeneration","volume":"9","author":"Heier","year":"2024","journal-title":"J. VitreoRetin. Dis."},{"key":"ref_60","unstructured":"Jaeb Center for Health Research (2024). Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD (DRCR Protocol AO CT.gov NCT05904028), Jaeb Center for Health Research."},{"key":"ref_61","first-page":"1097","article-title":"Prospective trial of Home OCT guided management of treatment experienced nAMD patients","volume":"10","author":"Holekamp","year":"2024","journal-title":"Retina"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Faes, L., Holekamp, N., Benyamini, G., Nahen, K., Mohan, N., and Freund, K.B. (Retin. Cases Brief Rep., 2025). Home Optical Coherence Tomography-guided Management of Type 3 Macular Neovascularization, Retin. Cases Brief Rep., online ahead of print.","DOI":"10.1097\/ICB.0000000000001792"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ajo.2024.10.031","article-title":"Home OCT and Sustained Delivery Approaches, a Perfect Marriage","volume":"277","author":"Holekamp","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"100772","DOI":"10.1016\/j.xops.2025.100772","article-title":"Pivotal Trial Validating Usability and Visualization Performance of Home OCT in Neovascular Age-Related Macular Degeneration: Report 1","volume":"5","author":"Heier","year":"2025","journal-title":"Ophthalmol. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"100662","DOI":"10.1016\/j.xops.2024.100662","article-title":"Pivotal Trial towards Effectiveness of Self-Administered OCT in Neovascular Age-related Macular Degeneration. Report Number 2\u2014Artificial Intelligence Analytics","volume":"5","author":"Schneider","year":"2024","journal-title":"Ophthalmol. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Leng, T., Leung, E.H., Mukkamala, S.K., Taban, M.R., Havilio, M., Nahen, K., Mohan, N., Benyamini, G., and Keenan, T.D. (2025). Longitudinal Validation of the Artificial Intelligence Algorithm in Home OCT for Age-Related Macular Degeneration. Report 3. Ophthalmol. Sci., 100907.","DOI":"10.1016\/j.xops.2025.100907"},{"key":"ref_67","unstructured":"Liu, L., Long, K., Chen, C., Yauch, L., Anegondi, N., Indjeian, V., Elliott, M., Liu, J., Sim, D., and Ferrara, D. (2025, January 18\u201320). Evaluation of Home OCT in Clinical Trial for Patients with Diabetic Macular Edema. Proceedings of the American Academy of Ophthalmology Meeting, Orlando, FL, USA."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Moon, B.-H., Kim, Y., and Kim, S.-Y. (2023). Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241613004"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/12\/2193\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:22:43Z","timestamp":1765459363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/12\/2193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":68,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["medicina61122193"],"URL":"https:\/\/doi.org\/10.3390\/medicina61122193","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}